{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    8,
    24,
    40,
    41,
    52,
    53,
    55,
    57
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Accelerated Elimination Procedure",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.1.1",
        "sectionTitle": "Noninvestigational medicinal product",
        "description": "Reference for procedure to be performed for male and female participants regarding contraception and sperm donation"
      },
      {
        "id": "ref_2",
        "name": "Highly Effective Contraception",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information",
        "description": "Reference for highly effective contraceptive methods for WOCBP"
      },
      {
        "id": "ref_3",
        "name": "Schedule of Activities",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Reference for pregnancy testing requirements and study data collection at discontinuation"
      },
      {
        "id": "ref_4",
        "name": "Country-specific Contraception",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.11",
        "sectionTitle": "Appendix 9: Country-Specific Requirements",
        "description": "Reference for specific requirements in UK, Germany, Denmark, etc."
      },
      {
        "id": "ref_5",
        "name": "Legally Authorized Representative",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.1.3",
        "sectionTitle": "Appendix 1: Regulatory, Ethical, and Study Oversight Considerations",
        "description": "Reference for ICF signature requirements for legally minor participants"
      },
      {
        "id": "ref_6",
        "name": "TB Screening",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.2",
        "sectionTitle": "Appendix 2: Clinical Laboratory Tests",
        "description": "Reference for tuberculosis screening test descriptions"
      },
      {
        "id": "ref_7",
        "name": "Liver Safety Algorithm",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.6",
        "sectionTitle": "Appendix 6: Liver and other safety: actions and follow-up assessments",
        "description": "Reference for IMP discontinuation criteria and laboratory abnormality follow-up"
      },
      {
        "id": "ref_8",
        "name": "Prohibited Medications",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.8",
        "sectionTitle": "Appendix 8A: Examples of drugs with a potential to change SAR442168 metabolism",
        "description": "Reference for CYP3A inducers and CYP2C8 inhibitors"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Sanofi corporation organized and existing under the laws of France is the ultimate parent of a worldwide group of affiliates including Sanofi US Services Inc., Sanofi Genzyme, and Genzyme Corporation",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Title Page",
        "pageNumber": 1
      },
      {
        "id": "annot_2",
        "text": "All assessments shall be done as designated in this SoA unless not permitted according to local regulations. All visit assessments should be performed during the visit window unless otherwise specified in this protocol.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "1.3 Schedule of Activities (SoA)",
        "pageNumber": 25
      },
      {
        "id": "annot_3",
        "text": "The Investigator may consult with an infectious disease expert if required, eg, test results are unclear or there is a suspicion of false positive test results.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "5.2 Exclusion Criteria",
        "pageNumber": 42
      },
      {
        "id": "annot_4",
        "text": "a one-time retest at screening may be performed if an abnormal laboratory test value is considered temporary.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "1.3 Schedule of Activities (SoA)",
        "pageNumber": 25
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "1",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2023-12-20",
        "description": "Amended Clinical Trial Protocol 11 (electronic 15.0). Rationale: include liver function test monitoring guidance and update co-medication guidance.",
        "amendmentNumber": "11"
      },
      {
        "id": "ver_2",
        "versionNumber": "1",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2023-11-17",
        "description": "Amended Clinical Trial Protocol 10 (electronic 14.0)",
        "amendmentNumber": "10"
      },
      {
        "id": "ver_3",
        "versionNumber": "1",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-02-28",
        "description": "Original Protocol (electronic 1.0)",
        "amendmentNumber": "Original"
      }
    ],
    "summary": {
      "referenceCount": 8,
      "annotationCount": 4,
      "versionCount": 3
    }
  }
}